Catalyst

Slingshot members are tracking this event:

APD334 (Etrasimod) in treating Ulcerative colitis Phase 2 data due Q1 2018

Source Link:
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-completes-full-enrollment-in-etrasimod-phase-2-clinical-study-for-ulcerative-colitis-300553908.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARNA Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Data previously expected 4Q 2016.
http://invest.arenap...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 19, 2018
Occurred Source:
http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-reports-positive-phase-2-results-oasis
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Ulcerative Colitis, Apd334
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.